Unicycive Therapeutics (UNCY) Projected to Post Quarterly Earnings on Wednesday

Unicycive Therapeutics (NASDAQ:UNCY) is projected to release its results before the market opens on Wednesday, November 12th. Analysts expect Unicycive Therapeutics to post earnings of ($0.62) per share for the quarter.

Unicycive Therapeutics (NASDAQ:UNCY) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.70) by $0.18. On average, analysts expect Unicycive Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Unicycive Therapeutics Price Performance

Shares of NASDAQ UNCY opened at $4.62 on Monday. Unicycive Therapeutics has a 1 year low of $3.71 and a 1 year high of $11.00. The firm has a 50-day moving average of $4.45 and a 200 day moving average of $5.11. The stock has a market cap of $81.59 million, a P/E ratio of -1.12 and a beta of 1.87.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $22.00 target price (up from $9.00) on shares of Unicycive Therapeutics in a report on Wednesday, October 29th. Wall Street Zen raised Unicycive Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, November 2nd. Benchmark lifted their price objective on Unicycive Therapeutics to $21.00 and gave the company a “speculative buy” rating in a research note on Monday, September 15th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Unicycive Therapeutics in a research note on Thursday, October 30th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.33.

Institutional Trading of Unicycive Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of UNCY. Vanguard Group Inc. lifted its holdings in shares of Unicycive Therapeutics by 8.7% during the third quarter. Vanguard Group Inc. now owns 658,878 shares of the company’s stock valued at $2,873,000 after purchasing an additional 52,925 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Unicycive Therapeutics by 11,698.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock worth $104,000 after buying an additional 21,525 shares in the last quarter. Finally, Lazard Asset Management LLC purchased a new position in Unicycive Therapeutics in the 2nd quarter worth about $55,000. Institutional investors own 40.42% of the company’s stock.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.